A novel sirtuin-3 inhibitor, LC-0296, inhibits cell survival and proliferation, and promotes apoptosis of head and neck cancer cells

Anticancer Research

Volumn 36, Issue 1, 2016, Pages 49-60

  Alhazzazi, Turki Y ^a,b   Kamarajan, Pachiyappan ^b   Xu, Yanli ^c   Ai, Teng ^c   Chen, Liqiang ^c   Verdin, Eric ^d   Kapila, Yvonne L ^b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HNSCC; Oral cancer; ROS; SIRT3; Sirtuin inhibitor; Sirtuin 3; Sirtuins

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; LC 0296; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS; HISTONE DEACETYLASE INHIBITOR; INDOLE DERIVATIVE; LC-0296; SIRT3 PROTEIN, HUMAN; SIRTUIN 3;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SYNTHESIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; HEAD AND NECK NEOPLASMS; LARYNGEAL NEOPLASMS; METABOLISM; MOUTH NEOPLASMS; PATHOLOGY; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMORADIOTHERAPY; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD AND NECK NEOPLASMS; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HISTONE DEACETYLASE INHIBITORS; HUMANS; INDOLES; KERATINOCYTES; LARYNGEAL NEOPLASMS; MOUTH NEOPLASMS; RADIATION TOLERANCE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SIRTUIN 3;

EID: 84958053556     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013.
2. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf
3. http://www.cancer.ca/en/cancer-information/cancer-101/cancerstatistics-at-a-glance/?region=ab
4. McGuinness D, McGuinness DH, McCaul JA and Shiels PG: Sirtuins, bioageing, and cancer. J Aging Res 40: 235754, 2011.
5. Verdin E, Hirschey MD, Finley LW and Haigis MC: Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 35: 669-675, 2010.
6. Sebastian C, Satterstrom FK, Haigis MC and Mostoslavsky R: From sirtuin biology to human diseases: an update. J Biol Chem 287: 42444-42452, 2012.
7. Yuan H, Su L and Chen WY: The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 6: 1399-1416, 2013.
8. Roth M and Chen WY: Sorting out functions of sirtuins in cancer. Oncogene 33: 1609-1620, 2014.
9. Alhazzazi TY, Kamarajan P, Verdin E and Kapila YL: Sirtuin-3 (SIRT3) and the Hallmarks of Cancer. Genes Cancer 4: 164-171, 2013.
10. Balcerczyk A and Pirola L: Therapeutic potential of activators and inhibitors of sirtuins. Bio Factors 36: 383-393, 2010.
11. Villalba JM and Alcain FJ Sirtuin activators and inhibitors. Biofactors 38: 349-359, 2012.
12. Bruzzone S, Parenti MD, Grozio A, Ballestrero A, Bauer I, Del Rio A and Nencioni A: Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr Pharm Des 19: 614-623, 2013.
13. Deng CX: SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 5: 147-152, 2009.
14. Lim CS: SIRT1: tumor promoter or tumor suppressor? Med Hypotheses 67: 341-344, 2006.
15. Alhazzazi TY, Kamarajan P, Verdin E and Kapila YL: SIRT3 and cancer: Tumor promoter or suppressor? Biochim Biophys Acta 1816: 80-88, 2011.
16. Fang Y and Nicholl MB: A dual role for sirtuin 1 in tumorigenesis. Curr Pharm Des 20: 2634-2636, 2014.
17. Bosch-Presegue L and Vaquero A: The dual role of sirtuins in cancer. Genes Cancer 2: 648-662, 2011.
18. Chen Y, Fu LL, Wen X, Wang XY, Liu J, Cheng Y and Huang JS: Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis 5: e1047. doi:10.1038/cddis.2014,14.
19. Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ and Kapila YL: Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 117: 1670-1678, 2011.
20. Kamarajan P, Alhazzazi TY, Danciu T, D'Silva NJ, Verdin E and Kapila YL: Receptor-interacting protein (RIP) and sirtuin-3 (SIRT3) are on opposite sides of anoikis and tumorigenesis. Cancer 118: 5800-5810, 2012.
21. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, Kim J, Yancopoulos G, Valenzuela D, Murphy A, Yang Y, Chen Y, Hirschey MD, Bronson RT, Haigis M, Guarente LP, Farese RV Jr., Weissman S, Verdin E, Schwer B: Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol 27: 8807-8814, 2007.
22. Cui H, Kamal Z, Ai T, Xu Y, More SS, Wilson DJ and Chen L: Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach. J Med Chem 57: 8340-8357, 2014.
23. Carey TE: Head and neck tumor cell lines. In: Atlas of Human Tumor Cell Lines. AGR Hay, J-G Park (eds.). Academic Press Inc./Harcourt. Brace Jovanovich Publishers; New York City, NY, pp. 79-120, 1994.
24. Fischel JL, Formento P and Milano G: Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (cetuximab). Impact on cell growth and molecular factors. Br J Cancer 92: 1063-1068, 2005.
25. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv enzyme reg 22: 27-55, 1984.
26. Grenman R, Burk D, Virolainen E, Wagner JG, Lichter AS and Carey TE: Radiosensitivity of head and neck cancer cells in vitro. A 96-well plate clonogenic cell assay for squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 114: 427-431, 1988.
27. Carey TE, Van Dyke DL, Worsham MJ, Bradford CR, Babu VR, Schwartz DR, Hsu S and Baker SR: Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UM-SCC-17A and UM-SCC-17B. Cancer Res 49: 6098-6107, 1989.
28. Szatrowski TP, Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798, 1991.
29. Toyokuni S, Okamoto K, Yodoi J and Hiai H: Persistent oxidative stress in cancer. FEBS lett 358: 1-3, 1995.
30. Huang JY, Hirschey MD, Shimazu T, Ho L and Verdin E: Mitochondrial sirtuins. Biochim Biophys Acta 1804: 1645-1651, 2010.
31. Lavu S, Boss O, Elliott PJ and Lambert PD: Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 7: 841-853, 2008.
32. Liu C, Huang Z, Jiang H and Shi F: The sirtuin 3 expression profile is associated with pathological and clinical outcomes in colon cancer patients. Biomed Res Int 871263, 2014.
33. Zhao Y, Yang H, Wang X, Zhang R, Wang C and Guo Z: Sirtuin-3 (SIRT3) expression is associated with overall survival in esophageal cancer. Ann Diagn Pathol 17: 483-485, 2013.
34. Yan SM, Han X, Han PJ, Chen HM, Huang LY and Li Y: SIRT3 is a novel prognostic biomarker for esophageal squamous cell carcinoma. Med Oncol 31: 103, 2014.
35. Yang M, Yang C and Pei Y: Effects of downregulation of SIRT3 expression on proliferation and apoptosis in esophageal squamous cell carcinoma EC9706 cells and its molecular mechanisms. Biomed Mater Eng 24: 3883-3890, 2014.
36. Wu WS: The signaling mechanism of ROS in tumor progression. Cancer Meta Rev 25: 695-705, 2006.
37. Behrend L, Henderson G and Zwacka RM: Reactive oxygen species in oncogenic transformation. Biochem Society Trans 31: 1441-1444, 2003.
38. Fleury C, Mignotte B and Vayssiere JL: Mitochondrial reactive oxygen species in cell death signaling. Biochimie 84: 131-141, 2002.
39. Gamaley IA and Klyubin IV: Roles of reactive oxygen species: signaling and regulation of cellular functions. Int Rev cytol 188: 203-255, 1999.
40. Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug resist updat 7: 97-110, 2004.
41. Pervaiz S and Clement MV: Tumor intracellular redox status and drug resistance-serendipity or a causal relationship? Curr pharma design 10: 1969-1977, 2004.
42. Qiu X, Brown K, Hirschey MD, Verdin E and Chen D: Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 12: 662-667, 2010.
43. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill, S, Hayes McDonald W, Olivier AK, Spitz DR and Gius D: Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 40: 893-904, 2010.
44. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, Singh KK, Abdulkadir SA, Spitz DR, Deng CX and Gius D: SIRT3 Is a Mitochondria-Localized Tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17: 41-52, 2010.
45. Boonstra J and Post JA: Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 337: 1-13, 2004.
46. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms:A radical therapeutic approach? Nature rev Drug discov 8: 579-591, 2009.
47. Montero AJ and Jassem J: Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 71: 1385-1396, 2011.
48. Sinclair DA and Guarente L: Small-molecule allosteric activators of sirtuins. Ann Rev Pharmacol Toxicol 54: 363-380, 2014.
49. Hu J, Jing H and Lin H: Sirtuin inhibitors as anticancer agents. Future Med Chem 6: 945-966, 2014.
50. Mahajan SS, Scian M, Sripathy S, Posakony J, Lao U, Loe TK, Leko V, Thalhofer A, Schuler AD, Bedalov A and Simon JA: Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J Med Chem 57: 3283-3294, 2014.
51. Chen B, Wang J, Huang Y and Zheng W: Human SIRT3 tripeptidic inhibitors containing N(epsilon)-thioacetyl-lysine. Bioorg Med Chem Lett 25: 3481-3487, 2015.
52. Kokkonen P, Kokkola T, Suuronen T, Poso A, Jarho E and Lahtela-Kakkonen M: Virtual screening approach of sirtuin inhibitors results in two new scaffolds. Eur J Pharm Sci 76: 27-32, 2015.
53. Pate K, Sherrill J, Mrksich M and Scholle MD: Discovery of SIRT3 inhibitors using SAMDI mass spectrometry. J Biomol Screen 20: 842-848, 2015.
54. Galli U, Mesenzani O, Coppo C, Sorba G, Canonico PL, Tron GC, Genazzani AA: Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2. Eur J Med chem 55: 58-66, 2012.
55. Salo HS, Laitinen T, Poso A, Jarho E and Lahtela-Kakkonen M: Identification of novel SIRT3 inhibitor scaffolds by virtual screening. Bioorg Med Chem Lett 23: 2990-2995, 2013.